title: Potassium-Binding Agents for the Clinical Management of Hyperkalemia.
abstract: Use of sodium polystyrene sulfonate (SPS) dominates the long-term treatment of hyperkalemia, but two new agents, sodium zirconium cyclosilicate and the recently FDA-approved patiromer, may offer potential advantages compared with SPS.
authors.forename: Martin
authors.initials: M
authors.lastname: Chaitman
authors.forename: Deepali
authors.initials: D
authors.lastname: Dixit
authors.forename: Mary Barna
authors.initials: MB
authors.lastname: Bridgeman
keywords: hyperkalemia; patiromer; sodium polystyrene sulfonate; sodium zirconium cyclosilicate